Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 387-391

  Azim Jr , Hatem A ^a   Metzger Filho, Otto ^a   De Azambuja, Evandro ^a   Loibl, Sibylle ^b   Focant, Florine ^a   Gresko, Ekaterina ^c   Arfi, Mounir ^d   Piccart Gebhart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Klinikum Offenbach   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

Author keywords

Breast cancer; Counseling; Fetal outcome; Pregnancy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONGENITAL MALFORMATION; CONTROLLED STUDY; DOWN SYNDROME; DRUG SAFETY; FEMALE; FETUS OUTCOME; HUMAN; INDUCED ABORTION; MAJOR CLINICAL STUDY; MATERNAL TREATMENT; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHASE 3 CLINICAL TRIAL; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; TOE MALFORMATION; TREATMENT DURATION;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860330520     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1996-6     Document Type: Article

References (23)

1. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer New Engl J Med 353 16 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
2. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer New Engl J Med 353 16 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
3. D Slamon W Eiermann N Robert T Pienkowski M Martin M Press J Mackey J Glaspy A Chan M Pawlicki T Pinter V Valero MC Liu G Sauter G von Minckwitz F Visco V Bee M Buyse B Bendahmane I Tabah-Fisch MA Lindsay A Riva J Crown 2011 Adjuvant trastuzumab in HER2-positive breast cancer New Engl J Med 365 14 1273 1283 21991949 10.1056/NEJMoa0910383 1:CAS:528:DC%2BC3MXht12mtLvN
4. ME Abusief SA Missmer ES Ginsburg JC Weeks AH Partridge 2010 The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer Cancer 116 4 791 798 20052714 10.1002/cncr.24835 1:CAS:528:DC%2BC3cXivFWqu7g%3D
5. TJ Matthews BE Hamilton 2009 Delayed childbearing: more women are having their first child later in life NCHS Data Brief 21 1 8 19674536
6. S Pant MB Landon M Blumenfeld W Farrar CL Shapiro 2008 Treatment of breast cancer with trastuzumab during pregnancy J Clin Oncol 26 9 1567 1569 18349415 10.1200/JCO.2008.16.0309
7. JM Beale J Tuohy SJ McDowell 2009 Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios Am J Obstet Gynecol 201 1 e13 e14 19398090 10.1016/j.ajog.2009.02.017
8. AA Bader D Schlembach KF Tamussino G Pristauz E Petru 2007 Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy Lancet Oncol 8 1 79 81 17196514 10.1016/S1470-2045(06)71014-2 (Pubitemid 46043032)
9. ID Witzel V Muller E Harps F Janicke M Dewit 2008 Trastuzumab in pregnancy associated with poor fetal outcome Ann Oncol 19 1 191 192 18084047 10.1093/annonc/mdm542 1:STN:280:DC%2BD1c%2FgtFaktA%3D%3D
10. HA Azim Jr FA Peccatori SJ Liptrott C Catania A Goldhirsch 2009 Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev 6 6 367 370 1:CAS:528:DC%2BD1MXms12gtb8%3D
11. HA Azim Jr H Azim FA Peccatori 2010 Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge Expert Rev Clin Immunol 6 6 821 826 20979546 10.1586/eci.10.77
12. F Amant S Deckers K Van Calsteren S Loibl M Halaska L Brepoels J Beijnen F Cardoso O Gentilini L Lagae O Mir P Neven N Ottevanger S Pans F Peccatori R Rouzier HJ Senn H Struikmans MR Christiaens D Cameron A Du Bois 2010 Breast cancer in pregnancy: recommendations of an international consensus meeting Eur J Cancer 46 18 3158 3168 20932740 10.1016/j.ejca.2010.09.010
13. HA Azim Jr L Santoro N Pavlidis S Gelber N Kroman H Azim FA Peccatori 2011 Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies Eur J Cancer 47 1 74 83 20943370 10.1016/j.ejca.2010.09.007
14. O Pagani A Partridge L Korde S Badve J Bartlett K Albain R Gelber A Goldhirsch 2011 Pregnancy after breast cancer: if you wish, ma'am Breast Cancer Res Treat 129 2 309 317 21698406 10.1007/s10549-011-1643-7
15. K Dalberg J Eriksson L Holmberg 2006 Birth outcome in women with previously treated breast cancer-a population-based cohort study from Sweden PLoS Med 3 9 e336 16968117 10.1371/journal.pmed.0030336 (Pubitemid 44455270)
16. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist P Sanchez Rovira MJ Piccart-Gebhart 2007 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 9555 29 36 17208639 10.1016/S0140-6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)
17. L Gianni U Dafni RD Gelber E Azambuja S Muehlbauer A Goldhirsch M Untch I Smith J Baselga C Jackisch D Cameron M Mano JL Pedrini A Veronesi C Mendiola A Pluzanska V Semiglazov E Vrdoljak MJ Eckart Z Shen G Skiadopoulos M Procter KI Pritchard MJ Piccart-Gebhart R Bell 2011 Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 3 236 244 21354370 10.1016/S1470-2045(11)70033-X 1:CAS:528:DC%2BC3MXjs1Cgur4%3D
18. JL Mills JL Simpson SG Driscoll L Jovanovic-Peterson M Van Allen JH Aarons B Metzger FR Bieber RH Knopp LB Holmes, et al. 1988 Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception New Engl J Med 319 25 1617 1623 3200277 10.1056/NEJM198812223192501 1:STN:280: DyaL1M%2FntVKgsQ%3D%3D (Pubitemid 19015234)
19. S Daniels M Johnston L Hiles 2011 Herceptin (trastuzumab) and the incidence of spontaneous abortion Drug Saf 34 987
20. HA Azim Jr FA Peccatori N Pavlidis 2010 Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors Cancer Treat Rev 36 2 101 109 20015593 10.1016/j.ctrv.2009.11.007 1:CAS:528:DC%2BC3cXjtFyhsLo%3D
21. N Pentsuk JW van der Laan 2009 An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies Birth Defects Res 86 4 328 344 10.1002/bdrb.20201 1:CAS:528:DC%2BD1MXhtV2isL3J
22. A Malek 2003 Ex vivo human placenta models: transport of immunoglobulin G and its subclasses Vaccine 21 24 3362 3364 12850340 10.1016/S0264-410X(03) 00333-5 1:CAS:528:DC%2BD3sXlt1eisL8%3D (Pubitemid 36792086)
23. E de Azambuja PL Bedard T Suter M Piccart-Gebhart 2009 Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4 2 77 88 19418111 10.1007/s11523-009-0112-2